HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas B Julian Selected Research

B 43

1/2021Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
11/2013Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas B Julian Research Topics

Disease

43Breast Neoplasms (Breast Cancer)
06/2022 - 10/2002
20Neoplasms (Cancer)
06/2022 - 10/2002
11Noninfiltrating Intraductal Carcinoma (DCIS)
01/2021 - 10/2004
3Margins of Excision
12/2019 - 02/2016
3Neoplasm Metastasis (Metastasis)
12/2019 - 07/2008
2Hypersensitivity (Allergy)
10/2010 - 10/2007
1Disease Progression
01/2022
1Lymphedema (Milroy Disease)
02/2019
1Neutropenia
01/2019
1Peripheral Nervous System Diseases (PNS Diseases)
01/2018
1Obesity
01/2018
1Pathologic Complete Response
10/2017
1Musculoskeletal Pain
02/2016
1Thrombosis (Thrombus)
02/2016
1Fatigue
02/2016
1Embolism (Embolus)
02/2016
1Erythema
01/2015
1Cytokine Release Syndrome
01/2015
1Abscess
09/2014
1Infections
09/2014
1Fat Necrosis
10/2010
1Carcinoma (Carcinomatosis)
06/2009
1Colorectal Neoplasms (Colorectal Cancer)
10/2008

Drug/Important Bio-Agent (IBA)

10TamoxifenFDA LinkGeneric
02/2018 - 08/2007
6Hormones (Hormone)IBA
06/2022 - 02/2016
6Estrogen ReceptorsIBA
01/2021 - 05/2008
5Progesterone Receptors (Progesterone Receptor)IBA
01/2021 - 05/2008
4Trastuzumab (Herceptin)FDA Link
01/2021 - 08/2007
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2018 - 10/2002
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2018 - 10/2002
2B 43IBA
01/2021 - 11/2013
2human ERBB2 proteinIBA
01/2021 - 10/2017
2Paclitaxel (Taxol)FDA LinkGeneric
02/2018 - 01/2017
2Docetaxel (Taxotere)FDA Link
01/2018 - 10/2002
2Anastrozole (Arimidex)FDA LinkGeneric
02/2016 - 02/2016
2Coloring Agents (Dyes)IBA
10/2010 - 10/2007
1AnthracyclinesIBA
06/2022
1palbociclibIBA
01/2019
1Letrozole (Femara)FDA LinkGeneric
01/2019
1ErbB Receptors (EGF Receptor)IBA
12/2018
1taxaneIBA
01/2018
1SolutionsIBA
01/2015
1CytokinesIBA
01/2015
1Anti-Bacterial Agents (Antibiotics)IBA
09/2014
1Biological ProductsIBA
08/2013
1Indicators and Reagents (Reagents)IBA
10/2012
1Estrogens (Estrogen)FDA Link
04/2012
1Dihydrotachysterol (AT 10)IBA
04/2012
1ParaffinIBA
02/2011
1dimemorfan (AT 17)IBA
06/2009
1Monoclonal AntibodiesIBA
10/2008
1Keratin-19 (Keratin 19)IBA
07/2008
1Aromatase InhibitorsIBA
05/2008
1Biomarkers (Surrogate Marker)IBA
05/2008

Therapy/Procedure

22Radiotherapy
01/2022 - 03/2004
21Segmental Mastectomy (Lumpectomy)
06/2022 - 03/2004
19Therapeutics
01/2022 - 08/2007
10Mastectomy (Mammectomy)
12/2019 - 06/2009
7Neoadjuvant Therapy
06/2021 - 10/2002
7Brachytherapy
09/2014 - 03/2004
5Drug Therapy (Chemotherapy)
06/2022 - 08/2010
5Adjuvant Chemotherapy
01/2020 - 05/2008
5Lymph Node Excision (Lymph Node Dissection)
10/2013 - 08/2007
3Catheters
09/2014 - 06/2009
2Simple Mastectomy
06/2022 - 10/2008
2Radical Mastectomy
01/2015 - 10/2008
2Conservative Treatment
01/2011 - 10/2010
1Retreatment
09/2014
1Adjuvant Radiotherapy
11/2012
1Conformal Radiotherapy
01/2011